Condition: Acute Coronary Syndrome · Interventional Cardiology · Sponsor: Fu Wai Hospital, Beijing, China
The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.
This description comes directly from the study's public registry record.
Haiyan Qian, MD, PhD · +8613811386143 · ahqhy712@163.com
Zhiyao Wei · +8615521192379 · weizhiyaoyx@163.com
Always discuss trial participation with your own doctor first.
| Fuwai Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04240834